HomeInsightsStock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Last Updated on: May 21, 2025

Key Highlights

  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2925 as of 21 May 14:34.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 55.8 on March 2024 . This represents a CAGR of -24.43% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 32917 crore on March 2024 . This represents a CAGR of 9.31% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 1015 crore as compare to the Dec '24 revenue of ₹ 984.49 crore. This represent the growth of 3.1% The revenue of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 428.84 crore as compare to the Dec '24 revenue of ₹ 399.28 crore. This represent the growth of 7.4%.
  • The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 373.87 crore as compare to the Dec '24 ebitda of ₹ 326.99 crore. This represent the growth of 14.34% The ebitda of OneSource Specialty Pharma Ltd for the Mar '25 is ₹ 184.72 crore as compare to the Dec '24 ebitda of ₹ 48.08 crore. This represent the growth of 284.19%.
  • The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 262.87 crore over 8 quarters. This represents a CAGR of 40.98% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -107 crore to ₹ 98.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 92.72 % on March 2024 . This represents a CAGR of -31.52% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
  • The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About OneSource Specialty Pharma Ltd

  • Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
  • The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
  • The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
  • Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same per...

Read more

14 May 2025 12:47

News

GlaxoSmithKline Pharmaceuticals AGM scheduled

GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the comp...

Read more

13 May 2025 17:18

News

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

13 May 2025 17:18

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

News

GlaxoSmithKline Pharmaceuticals revises board meeting date

GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which wa...

Read more

21 Jan 2025 11:16

OneSource Specialty Pharma Ltd News Hub

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

30 Apr 2025 11:35

News

OneSource Specialty Pharma to convene board meeting

OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on...

Read more

25 Jan 2025 10:23

News

Shares of Onesource Specialty Pharma list in T Group

The equity shares of Onesource Specialty Pharma (Scrip Code: 544292) are listed effective ...

Read more

24 Jan 2025 09:22

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of OneSource Specialty Pharma Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or OneSource Specialty Pharma Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 47,218 Cr while Market cap of OneSource Specialty Pharma Ltd is 18,901 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

As of May 21, 2025, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2787.3. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1651.75.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions